News & EventsFebruary 19, 2008 October 2007 July 3, 2007 |  Publications: Scientific PresentationsOur spore research with Charles Stark Draper Laboratory and Tufts University School of Medicine was presented as a poster “Detection and Differentiation of Bacillus Spores Using Pyrolysis: Differential Mobility Spectrometry and Genetic Algorithms” at the Pittcon Homeland Security and Forensics session, March 16, 2006. On May 15, 2005, at the annual meeting of the American Society of Clinical Oncologists (ASCO) in Orlando Florida, Correlogic made its first major presentation of the results of our breast cancer research with the Clinical Breast Care Project of Walter Reed Army Medical Center. Our poster, “A Serum Pattern Predictive of Breast Cancer” outlined progress in developing a diagnostic blood test for breast cancer. Using sera from 371 women with normal or benign breast conditions and sera from 234 women with invasive cancer, we generated a model that demonstrated 80.5 percent sensitivity and 94.4 percent specificity on a blinded set of 54 normal benign and 41 invasive cancer sera. Our collaboration with Walter Reed Army Medical Center is ongoing. On March 16, 2005, Correlogic’s Chief Science Officer, Ben Hitt, spoke before the Third Annual IBC Biomarker Pipeline Conference meeting in Boston. Dr. Hitt discussed the "Use of Seromic™ Patterns in Early Detection of Ovarian Cancer." On September 28, 2004, Dr. Timothy Coleman, Vice President of Research and Development for Correlogic, presented “A New Paradigm: Pattern Recognition and Clinical Proteomics” at BioJapan 2004. Dr. Coleman discussed the results of Correlogic’s ongoing research on pattern recognition in disease detection in the Pharmacoproteome symposium, chaired by Dr. Yoshiji Fujita, Professor of Molecular Biology and Biotechnology, University of Sheffield. BioJapan is held quadrennially and brings together leading research organizations and institutions from around the world. Correlogic's poster presentation "High-Throughput Multidimensional Mass Spectrometry Analysis for the Detection of Early Stage Epithelial Ovarian Cancer: A Serum Test for Ovarian Cancer." appeared at the Society of Gynecologic Investigation conference in Houston, TX on March 25, 2004. The poster presented results that were 97 percent sensitive and 94 percent specific in validation. On August 6, 2003, Ben Hitt presented “Changing the Prognosis for Ovarian Center: New Test for Early Detection”at the Strategic Research Institute’s Disease Management Conference in Boston, MA. Correlogic Systems and Advion BioSciences presented further methods development in a poster entitled “Application of Chip-Based, Automated Nanoelectrospray Mass Spectrometry for Proteomic Pattern Recognition” at the CHI Protein Biomarkers conference in Philadelphia, PA in August 2003. Utilizing an optimized samples preparation process, we obtained an improved model for ovarian cancer. At the July 2003 conference of the American Association for Cancer Research,
the NCI presented “Multiple High Resolution Serum Proteomic Patterns
for Ovarian Cancer Detection,” which detailed further improved results
achieved by the Correlogic/NCI/FDA team. On June 12, 2003, Correlogic Systems and Advion BioSciences presented a poster entitled “Development of a Proteome Marker Model for Ovarian Cancer Using Direct Analysis of Diluted Serum by Automated Nanoelectrospray TOF-MS” at the 51st meeting of the American Society for Mass Spectrometry in Montreal, Canada. The poster described our study of the use of Advion’s Nano Electrspray Ionization (nESI) in concert with Correlogic’s proprietary technology to model disease states. This represents the first published results from the co-development agreement announced on May 14, 2003. On May 28, 2003, Ben Hitt presented “Application of Pattern Discovery Technology to Biomarker Identification” at the Molecular Diagnostic and Targeted Therapeutics conference sponsored by IBC in Boston, MA. |